Key statistics
On Friday, TScan Therapeutics Inc (TCRX:NMQ) closed at 5.78, 54.96% above the 52 week low of 3.73 set on Nov 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.99 |
---|---|
High | 6.04 |
Low | 5.67 |
Bid | 5.50 |
Offer | 6.08 |
Previous close | 5.94 |
Average volume | 337.99k |
---|---|
Shares outstanding | 52.97m |
Free float | 48.27m |
P/E (TTM) | -- |
Market cap | 306.19m USD |
EPS (TTM) | -1.05 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
- TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
- TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
- TScan Therapeutics to Participate in Upcoming Investor Conferences
- TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- TScan Therapeutics Announces Updates to its Board of Directors
- TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
- TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
- TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
More ▼